HITIQ has secured a pivotal US patent for its Nexus technology. Picture Getty
Health & Biotech
HITIQ (ASX:HIQ), a leader in concussion management technologies, has been approved a US Patent relating to impact processing technology for its Nexus platform.
The US Patent and Trademark Office has issued a Notice of Allowance for HITIQ’s patent application, US 17/753,356, titled “Processing of Data Collected Via an Instrumented Mouthguard Device, Including Identification of False Impacts.”
The formal patent grant is expected in the coming months.
The company says this patent is crucial for HITIQ, as it supports the company’s foundational intellectual property protection in a key market.
HITIQ’s technology improves how impact data is processed and sorted, ensuring that the data from the playing field is accurate. This new method helps filter out false information caused by noisy environments, making the data more reliable.
Providing reliable data is a crucial part of the company’s business strategy and what sets it apart from competitors, allowing it to access numerous commercial opportunities in its target market, the company said.
“Receiving approval for our maiden US patent signals our technology as globally relevant and helps forge a pathway into the US, our key commercial jurisdiction,” said HITIQ’s CEO, Mike Vegar.
“This approval ensures our ability to protect an integral component of our product and technology in the largest addressable market within our product category.
“We will continue to build our global patent portfolio with our pipeline of IP activity to gradually emerge,” he added.
BlinkLab (ASX:BB1) has teamed up with the Mental Care Group (MCG) in Europe to enhance the diagnosis of ADHD (attention-deficit/hyperactivity disorder).
This partnership follows a successful pilot study, which confirmed that BlinkLab’s technology can effectively assess ADHD in clinical settings.
The collaboration with MCG, the fifth largest outpatient mental health provider in Europe, will help speed up the approval and adoption of BlinkLab’s smartphone-based app for ADHD diagnosis.
This app uses the phone’s sensors to measure how the eyes respond to sound, which helps identify ADHD symptoms more precisely.
The results from an initial study involving 184 participants showed that children with ADHD have heightened sensory sensitivity, which the app can objectively measure.
The partnership will expand the use of this technology, aiming to improve ADHD diagnosis and potentially apply it to other conditions in the future.
BlinkLab and MCG will also work together to obtain regulatory approval for the app, and to accelerate the path to clinical adoption and reimbursement.
The current study conducted in the Netherlands potentially could be used as part of the global ADHD study with BlinkLab opening additional recruitment and testing.
Now read: Can BlinkLab’s autism diagnosis tool replicate the huge success of ResApp?
Meanwhile, IDT Australia (ASX:IDT), a diversified pharmaceutical company, has reported impressive revenue growth for the final quarter of the fiscal year, surpassing expectations.
For the three months ending June 30, the company’s revenue jumped 87% to $4.6 million, marking its strongest quarter since starting a strategic transformation in late 2022.
Overall, IDT’s revenue for the full year reached $13.5 million, a 92% increase from the previous year and above its forecast range of $12.9 to $13.4 million.
The growth was driven by all three of the company’s main business areas.
The Advanced Therapies division saw the most dramatic increase, with quarterly revenue soaring to $1.1 million from just $60,000 a year ago.
The API Manufacturing sector also performed well, with revenue up 182% to $1.3 million.
Meanwhile, the Specialty Orals division grew by 6.7% to $1.9 million, showing recovery from past industry challenges.
At Stockhead we tell it like it is. While BlinkLab is a Stockhead advertiser, it did not sponsor this article.
Health & Biotech
Health & Biotech
Health & Biotech
